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Abstract:		
Osteosarcoma	 is	 the	most	common	primary	bone	 tumour	 in	children	and	adolescents	and	
advanced	 osteosarcoma	 patients	 with	 evidence	 of	 metastasis	 share	 a	 poor	 prognosis.	
Osteosarcoma	 frequently	 gains	 resistance	 to	 standard	 therapies	 highlighting	 the	 need	 for	
improved	treatment	 regimens	and	 identification	of	novel	 therapeutic	 targets.	Cancer	stem	
cells	(CSC)	represent	a	sub-type	of	tumour	cells	attributed	to	critical	steps	in	cancer	including	
tumour	propagation,	 therapy	 resistance,	 recurrence	and	 in	 some	cases	metastasis.	Recent	
published	 work	 demonstrates	 evidence	 of	 cancer	 stem	 cell	 phenotypes	 in	 osteosarcoma	
with	links	to	drug	resistance	and	tumorigenesis.	In	this	review	we	will	discuss	the	commonly	
used	 isolation	 techniques	 for	 cancer	 stem	 cells	 in	 osteosarcoma	 as	 well	 as	 the	 identified	
biochemical	and	molecular	markers.		
Keywords:	osteosarcoma,	bone	cancer,	cancer	stem	cell,	tumour	heterogeneity
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Cancer	stem	cells	and	tumour	heterogeneity:	what	do	we	know	about	osteosarcoma?	
Osteosarcoma	 predominantly	 initiates	 in	 the	 metaphysis	 of	 the	 long	 bones	 with	 a	 high	
prevalence	 in	 children	and	young	adults.	The	origin	of	a	 tumour	 is	potentially	a	 single	cell	
located	in	the	bone	marrow,	which	will	eventually	give	rise	to	a	polyclonal,	heterogeneous	
tumour	mass.	Analysis	of	 tumour	heterogeneity	allows	us	 to	decipher	 the	steps	 that	were	
taken	 from	 the	 initiating	 cell	 to	 the	 development	 of	 a	 heterogeneous	 tumour	 mass	
comprised	 of	 an	 array	 of	 distinguishable	 sub-clones.	 Indeed,	 osteosarcoma	 initiates	 as	 a	
monoclonal	disease,	which	quickly	develops	into	a	polyclonal	disease	and	is	considered	one	
of	 the	 most	 complex	 cancers	 in	 terms	 of	 molecular	 aberration.	 Deeper	 insight	 into	 this	
diversity	 therefore	 holds	 great	 promise	 to	 identify	 markers	 associated	 with	 the	 most	
aggressive	 tumour	 cells	 within	 a	 tumour	 mass.	 The	 vast	 heterogeneity	 found	 in	
osteosarcoma	is	shown	in	an	exome	sequencing	study	in	which	multiple	pathways	(14	driver	
genes)	were	identified	(1).	The	authors	suggest	that	no	single	driver	gene	can	be	pinpointed	
to	be	the	cause	of	the	majority	of	investigated	tumours	and	that	several	oncogenic	pathways	
cause	 genetic	 instability	 in	 osteosarcoma	 development.	 Importantly,	 this	 high	 level	 of	
heterogeneity	 adds	 increased	 complexity	 for	 effective	 treatment	 strategies,	 which	 is	
clinically	reflected	in	refractory	and	recurrent	disease.		
The	increasing	knowledge	of	the	cancer	genome	through	in	depth	analysis	using	for	
example	 deep	 sequencing	 has	 significantly	 added	 to	 the	 understanding	 of	 intra-tumour	
heterogeneity	and	an	evolutionary	pattern	of	a	subset	of	clones	within	a	tumour	has	been	
reported	(2).	New	technologies	now	allow	us	to	view	heterogeneity	also	on	a	single	cell	level.	
This	 has	 clearly	 increased	 the	 tumour	 complexity	 over	 performing	 analysis	 on	 bulk	 tissue	
showing	even	deeper	levels	of	intra-tumour	heterogeneity	in	many	cancer	types	(3-6).	Single	
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cell	 analysis	on	CSCs	 in	osteosarcoma	has,	 to	our	knowledge,	 currently	not	been	 reported	
but	could	significantly	help	to	understand	the	diversity	of	these	cells.		
	
Cells-of-origin	in	osteosarcoma	and	properties	of	cancer	stem	cells	
In	osteosarcoma	several	cell-of-origin	models	have	been	proposed	including	transformation	
of	undifferentiated	mesenchymal	stem	cells	 (MSCs)	as	well	as	more	committed	osteogenic	
progenitor	cells	(7)	(Figure	1).	Osteosarcoma	is	a	bone	forming	tumour	invading	frequently	
the	 surrounding	 soft	 tissues	 as	 revealed	 by	 conventional	 imaging	 associating	 X-ray	 and	
Magnetic	Resonance	 Imaging	 (MRI)	 (Figures	1A-C).	Osteosarcoma	 is	a	vascularized	 tumour	
characterized	 by	 typical	 osteoid	 matrix	 formed	 by	 cancer	 cells	 (Figures	 1D,E).	 Evidence	
comes	predominantly	from	in	vivo	studies	using	MSCs	and/or	osteoprogenitors	in	which	for	
example	 mutations	 in	 genes	 such	 as	 P53	 and	 RB	 and/or	 aberrant	 Hedgehog	 and	 NOTCH	
signalling	were	shown	to	induce	osteosarcoma	(7-9).	The	terminology	of	‘cancer	stem	cells’	
is	 still	 under	 debate	 with	 the	 association	 to	 stem	 cells	 remaining	 controversial.	 Indeed,	
cancer	 stem	 cells	 and	 cancer	 initiating	 cells	 are	 often	used	 interchangeably	 although	 they	
may	indeed	exhibit	different	properties.	In	a	cancer	stem	cell	model,	tumours	are	thought	to	
be	hierarchically	organised	with	a	subpopulation	of	self-renewing	cells	at	the	basis	of	tumour	
progression	(10).	These	cancer	stem	cells	(CSCs)	are	proposed	to	be	unique	subsets	of	clones	
within	a	tumour	mass	attributed	with	tumour	propagation,	resistance	to	therapy	and	have	in	
some	 studies	been	attributed	 to	 initiate	metastases.	 Evidence	exists	 in	osteosarcoma	 that	
patients	 may	 present	 with	 distant	 metastases	 decades	 after	 completion	 of	 their	 first	
treatment	 (11)	 potentially	 further	 highlighting	 the	 tumorigenic	 characteristics	 of	 CSCs	
although	 this	 currently	 remains	 speculative.	 Similar	 to	 the	 origin	 of	 osteosarcoma,	 the	
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existing	 hypotheses	 for	 the	 origin	 of	 CSCs	 in	 general	 include	 the	 transformation	 of	
undifferentiated	stem	cells	or	more	committed	cells	to	gain	aberrant	self-renewal	properties	
(12).	 Remarkably,	 a	 stem	 cell	 transcription	 factor	 (Sox2)	 has	 been	 shown	 to	 maintain	
osteosarcoma	 CSCs	 (13)	 through	 inhibition	 of	 the	 Hippo	 pathway	 (14).	 The	 complex	 self-
renewal	 process	of	 normal	 stem	 cells	 (15)	 is	 partly	 regulated	by	 external	 signals	 from	 the	
surrounding	microenvironment,	 the	 stem	 cell	 niche.	 Such	 a	 specialised	microenvironment	
has	also	been	proposed	for	CSCs,	influencing	CSC	function	and	survival	and	in	some	cancers	
these	 niches	 (e.g.	 vascular,	 immune,	 bone)	 may	 even	 overlap	 with	 the	 normal	 stem	 cell	
niche	(16).	 In	addition,	the	bone	niche	and	the	bone	microenvironment	that	osteosarcoma	
cells	 and	 the	 putative	 CSCs	 are	 surrounded	 by	 apply	 continuous	 pressure	 thus	 further	
influencing	genomic	instability,	dormancy	and	potential	new	resistant	mechanisms	(17).		
	
Methods	to	identify	cancer	stem	cells		
Several	 methods	 have	 been	 developed	 to	 identify	 and	 isolate	 CSCs	 based	 on	 their	 self-
renewal	properties	and	have	been	discussed	 in	detail	elsewhere	(10,	18,	19).	Functional	 in	
vitro	assays	are	frequently	initially	applied	to	enrich	for	CSCs.	This	is	often	followed	by	more	
descriptive	 assays	 and	 in	 vivo	 verification;	 however,	 the	 order	 and	 selection	 of	 the	 tests	
appears	 to	 be	 interchangeable	 depending	 on	 the	 study.	 The	 functional	 in	 vitro	 test	 of	
formation	of	tumour	spheres	under	non-adherent	and	serum-free	conditions	often	serves	as	
the	 initial	 step	 to	enrich	 for	CSC-like	 cell	 populations	 (Figure	1F).	 The	 standard	method	 to	
verify	 CSC	 candidates	 in	 vivo	 is	 the	 serial	 transplantation	 of	 isolated	 putative	 CSCs	 into	
immunocompromised	mice	to	assess	tumorigenic	capacity	at	low	cell	numbers.	Both	the	 in	
vivo	 and	 in	 vitro	 functional	 assays	 have	 the	 disadvantage	 that	 truly	 quiescent	 CSCs	 will	
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possibly	not	be	 identified.	 The	 functional	methods	are	 frequently	used	 in	 connection	with	
descriptive	assays	 like	the	measurement	of	gene	expression	 levels	of	stem-like	 factors	and	
identification	based	on	cell	surface	markers.	In	order	to	assess	cell	populations	for	proposed	
drug	resistance	properties	side	population	analysis	(dye	exclusion	assay	and	ALDH	(aldehyde	
dehydrogenase)	activity	are	frequently	applied	to	enrich	for	CSCs	with	these	characteristics.	
Importantly,	 all	 methods	 require	 careful	 consideration	 because	 under	 none	 of	 these	
experimental	conditions	a	pure	CSC	population	or	detection	of	all	CSC	sub-populations	can	
be	assumed.	The	methods	are	more	 likely	to	enrich	the	sample	for	 (specific)	CSCs	through	
experimentally-induced	 selection	and	 in	 some	cases	environmental	pressure.	 The	use	of	 a	
number	 of	 methods	 including	 functional	 experiments	 and	 careful	 interpretation	 should	
therefore	be	applied	to	CSC	research.	
	
Identification	of	cancer	stem	cells	in	osteosarcoma		
In	the	following	section	the	main	identified	markers	and	evidence	for	the	existence	of	CSCs	
in	 osteosarcoma	 will	 be	 discussed.	 The	 studies	 were	 grouped	 based	 on	 their	 initial	
enrichment	method	and	an	overview	can	be	found	in	table	1.	
	
Side	population	(dye	exclusion	assays)	
One	main	feature	of	CSCs	is	their	potential	to	evade	treatment	and	it	is	suggested	that	this	is	
achieved	 through	 an	 increase	 in	 ATP-binding	 cassette	 (ABC)	multidrug	 efflux	 transporters	
such	as	MDR1/ABCB1	and	BRCP1/ABCG2	and	ABCB5	expression.	This	trait	has	been	used	for	
CSC	 identification	 by	measuring	 the	 ability	 of	 cells	 to	 exclude	 DNA-binding	 dyes	 (Hoechst	
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33342	or	Rhodamine	123)	by	fluorescence-activated	cell	sorting	(18,	20-22).	Cells	expressing	
high	ABC	transporters	exclude	the	dyes	and	are	visible	as	a	‘side	population’	during	analysis.	
Murase	et	al	 (23)	studied	the	side	population	fraction	 in	seven	osteosarcoma	cell	 lines	but	
only	one	line	(NY)	was	reported	to	have	a	side	population	fraction	while	side	population	cells	
were	 hardly	 detected	 in	 the	 rest	 of	 the	 cell	 lines.	 They	 also	 studied	 one	 bone	 human	
malignant	 fibrous	 histiocytoma	 cell	 line	 (MFH2003)	which	was	 shown	 to	 have	 the	 largest	
side	 population	 fraction	 and	 to	 exhibit	 increased	 ABCG5	 expression	 as	 well	 as	 cancer-
initiating	 characteristics	 detected	by	 increased	 sphere	 formation	 and	 tumour	 formation	 in	
vivo	when	compared	to	non-side	population	cells.	
	 A	higher	detection	rate	of	side	population	cells	in	osteosarcoma	was	shown	in	human	
primary	samples	(24).	Downstream	analysis	of	the	side	population	cells	showed	upregulated	
gene	 expression	 (ABC	 transporters,	 Oct4,	 Nanog),	 increased	 sphere	 formation	 and	 higher	
multidrug	 resistance	 to	 doxorubicin,	 methotrexate	 and	 cisplatin	 compared	 to	 non-	 side	
population	cells.	When	injected	into	immunocompromised	mice,	the	proposed	CSCs	showed	
higher	 tumorigenic	 potential	 although	 non-side	 population	 cells	 at	 higher	 numbers	 could	
also	 form	 tumours.	 Similar	 experiments	 carried	 out	 with	 U2OS	 cells	 did	 not	 show	 a	 side	
population	fraction.		
	
Aldehyde	dehydrogenase	(ALDH)	
A	second,	frequently	investigated	approach	through	which	CSCs	apply	their	chemoresistance	
is	 the	 expression	 and	 activity	 of	 the	 drug-detoxifying	 enzyme	 ALDH.	 A	 subpopulation	 of	
ALDH1
high
	MG63	cells	was	detected	by	Honoki	et	al	(25)	who	further	reported	ALDH1
high
	cells	
to	 have	 increased	 expression	 of	 stem-like	 genes	 (Nanog,	 Oct3/4,	 Stat3,	 Sox2),	 higher	
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resistance	to	doxorubicin	and	cisplatin	and	increased	self-renewal	ability	as	shown	by	sphere	
formation.	 Importantly,	ALDH
high
	 cells	were	also	detected	 in	human	osteosarcoma	samples	
and	increased	ALDH	activity	was	further	correlated	to	metastatic	potential	(26).	It	was	also	
shown	that	inhibition	of	ALDH	activity	using	disulfiram	resulted	in	reduced	cell	proliferation	
suggesting	 direct	 targeting	 of	 CSC	 phenotype	 cells.	 A	 second	 study	 reported	 large	 ALDH-
bright	cell	population	in	the	OS99-1	osteosarcoma	cell	line	compared	to	lower	percentages	
in	 Hu09,	 Saos-2	 and	 MG63	 (27).	 Interestingly,	 injection	 of	 the	 OS99-1	 cells	 into	 mice	
followed	by	ALDH	activity	measurement	showed	a	lower	ALDH-bright	fraction	compared	to	
the	 parental	 line	 cultured	 in	 vitro.	 The	ALDH-bright	 cells	were	 further	 characterised	 to	 be	
more	 tumorigenic	 in	 vivo	 and	 exhibit	 higher	 stem	 like	 gene	 expression	 (Nanog,	 Sox-2,	
OCT3/4)	compared	to	ALDH-low	cells.	
	
Cell	surface	markers	
Cell	surface	markers	are	arguably	the	most	attractive	and	sought	after	identification	method	
of	 CSCs.	 A	 specific	 cell	 surface	marker	 exclusively	 to	 CSCs	 and	 not	 normal	 cells,	 including	
stem	cells,	would	drastically	simplify	the	isolation	and	treatment	potential	for	these	cells.		
	
CD133	(prominin)	
Tirino	et	al	(28)	showed	that	CD133,	a	membrane	glycoprotein,	may	be	a	marker	of	CSCs	in	
osteosarcoma.	CD133
+
	cells	were	 identified	 in	three	osteosarcoma	cell	 lines	(Saos2,	MG63,	
U2OS).	 The	 CD133
+
	 cells	were	 further	 characterised	 to	 be	more	 proliferative,	 overexpress	
OCT3/4	and	ABCG2,	have	a	small	side	population	fraction	and	formed	spheres	in	serum-free	
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conditions	while	CD133
-
	cells	did	not.	Interestingly,	the	authors	detected	intracellular	CD133	
staining	in	CD133
+
and	CD133
-
	cells	and	reported	that	mRNA	levels	of	CD133	were	identical	
between	the	two	populations.	The	group	was	unable	to	grow	CD133
+
	or	CD133
-	
tumours	 in	
vivo.	 In	 a	 follow	up	 study,	 CD133
+
	 cells	were	 shown	 to	be	present	 in	 two	human	primary	
osteosarcomas	 and	 exhibiting	 stem-like	 gene	 expression	 (e.g.	 OCT3/4,	 Nanog),	 sphere	
formation	and	side	population	fractions	(29).	In	addition,	cells	isolated	from	CD133
+
	derived	
spheres	 were	 shown	 to	 form	 large	 tumours	 in	 vivo	 compared	 to	 the	 adherent	 cells.	
Interestingly,	in	both	studies	it	was	shown	that	CD133
+
	cells	could	give	rise	to	CD133
-
	cells	in	
culture	suggesting	a	phenotypic	switch.	
The	expression	of	CD133	on	FFPE	samples	of	human	osteosarcoma	was	shown	by	He	
et	 al	 (30)	 who	 detected	 the	 marker	 on	 46	 out	 of	 70	 analysed	 samples	 and	 positively	
correlated	 CD133	 expression	 with	 lung	 metastases	 and	 decreased	 overall	 survival.	 In	
addition,	characterisation	of	MG63	cells	showed	that	CD133
+
	subsets	were	more	migratory,	
invasive	 and	 overexpressed	 Oct4,	 Nanog	 and	 CXCR4.	 CD133
+
	 cells	 in	 patient	 samples	 of	
osteosarcoma	and	a	CD133
+
	sub-population	in	Saos2	cells	were	also	reported	by	Li	et	al	(31).	
A	 comprehensive	assessment	of	CD133	expression	and	associated	CSC	phenotypes	on	 cell	
lines	(Saos2,	U2OS,	MG63,	HOS,	MNNG/HOS,	143B)	and	primary	tumours	was	followed	by	in	
depth	analysis	of	miRNA	expression	profiling	which	 identified	miR-133a	 in	connection	with	
CD133	expression	(32).	The	micro	RNA	was	further	shown	to	regulate	tumorigenic	potential	
since	 silencing	 in	 combination	with	 chemotherapeutic	 treatment	 significantly	 reduced	 the	
aggressive	tumour	type	and	 lung	metastases	 in	vivo.	 Interestingly,	CD133	expression	could	
be	 induced	 by	 chemotherapy	 treatment	 and	 was	 associated	 with	 enhanced	 miR-133a	
expression	 suggesting	 a	 CSC	 induction	 through	 therapeutic	 challenge.	 Overall,	 CD133	
appears	as	potential	 therapeutic	 target	 in	osteosarcoma	and	pharmacologic	 induction	of	a	
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switch	 from	 the	CD133+	 to	CD133-	phenotype	 through	 siRNA	 could	be	 a	new	 therapeutic	
approach.	
CD117	(c-kit),	Stro-1	
A	 study	 assessing	 the	 feasibility	 of	 using	 MSC	 surface	 markers	 to	 enrich	 for	 CSCs	 in	
osteosarcoma	was	done	by	Adhikari	et	al	(33),	who	convincingly	showed	that	CD117
+
/Stro-1
+
	
double-positive	cells	were	present	 in	mouse	and	human	osteosarcoma	cell	 lines	as	well	as	
primary	cultures.	Intriguingly,	the	double-positive	fraction	showed	higher	sphere	formation	
ability,	increased	resistance	to	doxorubicin	treatment	and	overexpressed	CXCR4	and	ABCG2.		
Furthermore,	double-positive	cells	more	readily	formed	tumours	at	a	lower	cell	number	and	
it	was	shown	that	this	CSC	fraction	had	increased	metastatic	potential	compared	to	double	
negative	 cells.	 This	 study	 was	 one	 of	 the	 first	 to	 comprehensively	 assess	 the	 molecular	
constitution	of	the	identified	CSCs	and	to	furthermore	show	functional	CSC	characteristics	in	
a	number	of	experiments.		
	
CD271	
CD271	 is	 a	 neural	 crest	 low-affinity	 nerve	 growth	 factor	 receptor	 and	 a	 marker	 of	 bone	
marrow	mesenchymal	stem	cells.	A	study	 investigating	 the	stem	 like	phenotype	 in	CD271
+
	
cells	was	performed	by	 Tian	et	 al	 (34).	 CD271
+
	 cells	were	 found	on	 FFPE	 tissue	of	 human	
osteosarcoma	 samples	 and	 the	 cell	 lines	 MNNG/HOS,	 U2OS	 and	 Saos2	 also	 contained	
CD271
+
	 subpopulations.	 The	 authors	went	 on	 to	 show	 that	 CD271
+
	 cells	 had	 upregulated	
stem	cell	gene	expression,	 resistance	to	chemotherapy	and	were	more	readily	detected	 in	
spheres.	When	CD271
+
	and	CD271
-	
cells	were	separated	the	CD271
+
	fraction	showed	higher	
	 11	
tumorigenic	 potential	 in	 the	 sphere	 formation	 assay	 and	 when	 injected	 into	
immunocompromised	mice.		
	
Sphere	formation	assays	
Tissue	stem	cells	have	been	 identified	through	the	ability	of	cells	 to	 form	spheres	and	this	
method	 has	 also	 been	 used	 to	 assess	 CSC	 presence.	 Sarcospheres	 (spheres	 growing	 from	
sarcoma	cells)	have	been	grown	under	similar	experimental	set	ups	to	those	published	for	
neural	stem	cells	including	non-adherent,	serum-free	conditions	and	the	supplementation	of	
media	with	growth	factors	(N2,	epidermal	growth	factor	etc.).		
The	first	to	describe	osteosarcoma	stem	cells	using	sphere	formation	was	Gibbs	et	al	
in	2005	(35).	This	was	followed	by	several	other	groups,	which	further	showed	that	sphere	
forming	 cells	 were	 tumorigenic	 in	 immunodeficient	mice	 and	 that	 these	 cells	 were	more	
drug	 resistant	 suggesting	 a	 CSC	 phenotype	 (36).	 A	 detailed	 study	 on	 the	 sphere	 forming	
fraction	of	MNNG/HOS	 cells	was	done	by	Martins-Neves	et	 al	 (37)	who	 showed	 that	 cells	
isolated	 from	 spheres	 had	mesenchymal	 stem	 cell	 properties	 including	 upregulated	 gene	
expression	of	stemness	genes	Oct3/4,	Nanog,	and	ABC	transporters.	They	went	on	to	show	
that	 sphere	 cells	were	more	 resistant	 to	 chemotherapy	and	 radiation	and	 that	 these	 cells	
exhibited	higher	 cancer-initiating	 properties	 in	 vivo	when	 compared	 to	 parental	 cells.	 It	 is	
noteworthy	that	the	main	CSC	selection	method	was	sphere	formation	suggesting	that	the	
experimental	 conditions	 of	 this	 assay	 induced	 CSC-like	 characteristics.	 Indeed,	 the	 same	
group	 later	 showed	 that	 the	 selection	 or	 enrichment	method	 (i.e.,	 sphere	 forming	 ability,	
side	population	analysis	or	ALDH	activity)	applied	to	each	cell	line	of	a	larger	panel	was	pre-
selecting	CSCs	with	specific	and	dissimilar	characteristics	in	single	cell	lines	(38).	Importantly,	
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these	 data	 suggest	 that	 CSCs	 with	 specific	 molecular	 and	 functional	 characteristics	 are	
enriched	depending	on	the	methods	and	thus	heterogeneous	CSC	sub-populations	may	exist	
side	by	side	in	one	and	the	same	cancer	cell	line.	To	our	knowledge	this	study	is	one	of	very	
few	applying	several	 initial	CSC	enrichment	methods	on	the	same	samples	thus	suggesting	
that	heterogeneity	may	be	present	within	the	osteosarcoma	CSC	population.	
The	potential	plasticity	of	the	CSC	phenotype	in	osteosarcoma	was	shown	by	Zhang	
et	 al	 (39).	 The	 authors	 presented	 that	MNNG/HOS,	 Saos2	 and	MG63	 cells	 readily	 formed	
spheres	and	that	treatment	with	TGFβ1	or	application	of	hypoxic	conditions	(both	abundant	
in	 the	 bone	 microenvironment)	 significantly	 increased	 sphere	 formation	 suggesting	 an	
induction	of	CSCs	through	environmental	factors.	Sphere	cells	had	increased	stem	like	factor	
and	ABC	transporter	expression	levels,	increased	resistance	to	cisplatin	and	adriamycin	and	
in	vivo	tumour	formation.	The	role	of	TGF	in	general	tumour	progression	was	widely	studied	
and	its	role	in	osteosarcoma	suspected	(40).!Indeed,	the	relevance	of	TGFβ1	to	propagate	a	
stem	 like	 phenotype	 in	 osteosarcoma	 was	 shown	 when	 inhibition	 of	 the	 TGFβ1-receptor	
resulted	 in	 reduced	 sphere	 formation.	 In	 vivo	 experiments	 using	 CSCs	 from	 spheres,	 CSCs	
from	 TGFβ1-induced	 spheres	 and	 parental	 cells	 further	 confirmed	 the	 enrichment	 of	
aggressive	 CSCs	 in	 the	 TGFβ1-induced	 sphere	 population	 since	 this	 group	was	 capable	 of	
forming	 the	most	 tumours.	 The	 authors	 concluded	 that	 CSCs	may	 develop	 de	 novo	 from	
differentiated	 cancer	 cells	 and	 that	 they	 can	 revert	 back	 into	 a	more	 differentiated	 state	
underlining	 a	 potential	 of	 plasticity.	 In	 addition,	 the	 study	 elegantly	 highlights	 the	
importance	of	the	microenvironment	(or	experimental	conditions)	for	CSCs.		
MicroRNAs	 (miRNA)	 regulate	 gene	 expression	 on	 a	 post-transcriptional	 level	 and	
have	been	proposed	to	be	involved	in	cancer	progression	and	initiation.	The	micro	RNA	miR-
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26a	was	 shown	 to	 be	 significantly	 lower	 in	 sarcospheres	 or	 the	 ALDH	 positive	 fraction	 of	
several	osteosarcoma	cell	 lines	compared	to	the	parental	lines	(41).	Doxorubicin	treatment	
also	reduced	miR-26a	levels	suggesting	an	increase	in	stem	like	cells	after	treatment	and	a	
correlation	between	low	miR-26a	levels	and	CSCs.	This	was	confirmed	since	over-expression	
of	miR-26a	significantly	reduced	gene	expression	of	stemness	markers,	resulted	in	fewer	and	
smaller	 spheres,	 formed	 fewer	 tumours	and	 increased	 the	sensitivity	 to	chemotherapeutic	
challenge	compared	to	control.	As	a	mechanism	the	group	suggested	that	miR-26a	reduces	
osteosarcoma	malignancy	via	Jagged1	(notch	pathway)	suppression.	Importantly,	analysis	of	
miR-26a	 levels	 in	 patient	 samples	 linked	 high	 levels	 to	 a	 better	 prognosis.	 Finally,	 a	 link	
between	 osteosarcoma	 CSCs	 and	 telomerase	 activity	 was	 reported	 by	 Yu	 et	 al	 after	
detection	of	cells	with	high	telomerase	activity	under	sphere	formation	conditions	(42).		
	
Induction	of	cancer	stem	cell	phenotype	through	chemotherapeutic	treatment	
The	presence	of	a	therapy-resistant,	tumorigenic	sub-population	of	cancer	cells	in	a	tumour	
is	 visible	 in	 patients	 with	 refractory	 disease	 and	 significantly	 highlights	 the	 necessity	 to	
further	 understand	 the	 nature	 of	 these	 cells.	 This	 chemoresistant	 characteristic	 has	 been	
exploited	 in	 a	 few	 studies	 investigating	 whether	 chemotherapy	 treated	 or	 treatment-
resistant	 cells	 could	 contain	 CSCs	 (43-46).	 Indeed,	 it	 was	 shown	 that	 methotrexate	 pre-
treated	or	resistant	cells	not	only	expressed	CD117
+
/Stro-1
+
	and	had	a	side	population	but	
that	these	cells	also	formed	more	spheres	in	vitro	and	were	more	tumorigenic	when	injected	
subcutaneously	 into	 immunodeficient	 mice	 (44).	 The	 finding	 that	 cells	 with	 CSC	
characteristics	could	be	enriched	by	treatment	via	activated	Notch	signalling	pathways	was	
shown	in	a	recent	study	using	cisplatin-resistant	143B	and	U2Os	cells	(46).	Cisplatin-resistant	
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cells	were	enriched	for	CD117
+
/Stro-1
+
	double-positive	cells,	formed	more	spheres	and	were	
more	 tumorigenic	 in	 vivo.	 Importantly,	 the	 group	 also	 assessed	 relapsed	 tumours	 after	
cisplatin	treatment	in	vivo	and	reported	an	increase	in	CSCs	with	elevated	Oct4,	Sox2,	CD117,	
Stro-1	levels	and	sphere	formation	capability.			
The	exploitation	of	chemoresistant	cancer	cell	traits	was	also	used	by	Martins-Neves	
et	al	(43)	who	found	that	stem-like	cells	could	be	induced	with	chemotherapy	treatment	in	a	
number	 of	 fibroblastic	 and	 osteoblastic	 osteosarcoma	 cell	 lines.	 The	 identified	 treatment-
induced	cells	had	increased	ALDH
high
	populations,	upregulated	ABC	transporters	and	showed	
overexpression	 of	 stemness	 genes	 as	 well	 as	 Wnt/beta-catenin	 signalling	 pathways.	 The	
stem	 like	 features	could	be	 reduced	when	the	Wnt/beta-catenin	pathway	was	 inhibited	 in	
vitro	and	it	was	shown	that	a	combination	of	chemotherapy	and	Wnt-inhibitor	was	the	most	
efficacious	 anti-tumour	 treatment	 in	 vivo.	 The	 findings	 of	 the	 induction	 of	 a	 stem-like	
phenotype	through	chemotherapy	were	strengthened	with	the	correlation	of	‘poor	response’	
to	chemotherapy	and	stem-like	gene	expression	in	osteosarcoma	patients.	The	selection	of	
an	 aggressive	CSC	phenotype	after	 cisplatin	 treatment	 could	be	 suggested	by	 the	work	of	
Tsuchida	 et	 al	 (45).	 Side	 population	 cells	 of	 the	 HOS	 cell	 line	 treated	 or	 not	 treated	with	
cisplatin	were	isolated	and	while	cisplatin-induced	side	population	cells	formed	tumours	 in	
vivo	 the	 side	 population	 fraction	 isolated	 from	 untreated	 cells	 did	 not.	 Furthermore,	
cisplatin-induced	 activation	 of	 VEGF/Flt1	 signalling	was	 reported	 to	 accumulate	 the	 highly	
tumorigenic	CSC-type	cells.		
Collectively	the	reports	using	chemotherapeutics	show	that	a	CSC	phenotype	can	be	
induced	 through	 therapeutic	 challenge.	 It	 remains	 to	 be	 established	 whether	 different	
chemotherapeutic	challenges	will	give	rise	to	different	CSC	sub-populations.	
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Conclusion	
The	debate	about	a	cancer	stem	cell	definition	is	still	ongoing	and	importantly	it	is	not	clear	
whether	 the	 stem	 cell	 phenotype	 of	 a	 cancer	 cell	 is	 intrinsic	 or	 plastic.	 Tumour	 cells	 can	
switch	in	and	out	of	a	stem	cell	phenotype	further	 increasing	the	complexity	of	the	cancer	
stem	 cell	 hypothesis	 and	 suggesting	 that	 environmental	 pressure	 (experimental	 or	 in	
patients)	 may	 be	 a	 trigger	 for	 heterogeneity	 and	 plasticity.	 For	 example	 increased	
environmental	 pressure	 through	 chemotherapy	 treatment	 has	 the	 potential	 to	 induce	 a	
switch	 from	a	differentiated	 towards	a	 stem-like	phenotype	 in	osteosarcoma	 (43-46).	 This	
potential	plasticity	and	 the	many	different	experimental	enrichment	methods	may	help	 to	
understand	the	variations	of	reported	CSC	markers	between	studies.	Importantly	it	appears	
that	the	enriched	CSC	phenotype	may	depend	on	the	applied	isolation	method(s),	however,	
more	 studies	 are	 required	 to	 verify	 this.	 Moreover,	 it	 is	 currently	 unclear	 whether	 CSCs	
inherently	exhibit	metastasis-initiating	properties.		
The	 high	 level	 of	 heterogeneity	 found	 in	 osteosarcoma,	 including	 the	 effect	 of	 the	
tumour	microenvironment	may	be	more	comprehensively	assessed	in	PDX	(patient	derived	
xenograft)	models	and	evidence	exists	that	cells	with	CSC	phenotype	are	present	in	patient	
derived	osteosarcoma	samples	(24,	46).	The	use	of	patient	derived	material	could	potentially	
not	 only	 reflect	 the	 high	 heterogeneity	 of	 this	 rare	 cancer	 but	 would	 also	 reflect	 the	
influence	of	the	human	microenvironment	in	more	detail	compared	to	studies	on	cell	lines.	
Despite	 these	potential	advantages	 the	approach	may	be	 limited	by	 the	 low	availability	of	
primary	chemonaive	tumours.	The	potential	expansion	of	CSCs	through	the	growth	of	PDX	
material	 in	vivo	 could	possibly	help	overcome	this	 limitation	and	 requires	 further	 in	depth	
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investigation	 in	 both	 model	 development	 and	 CSC	 research	 in	 these	 models.	 Moreover	
technical	 refinements	 and	 research	 on	 novel	 techniques	may	 allow	 the	 identification	 and	
isolation	of	pure	subpopulations	of	CSCs	from	osteosarcoma.	The	major	goal	and	biological	
interest	 of	 CSC	 research	 is	 the	 identification	 of	 specific	 treatment	 targets	 to	 effectively	
deplete	CSCs.	Several	studies	have	 linked	CSCs	directly	to	clinical	events	 (24,	30,	41,	43)	 in	
osteosarcoma	and	treatment	studies	have	reported	inhibition	of	osteosarcoma	CSCs	or	the	
CSC	phenotype	(reviewed	in	7)	suggesting	that	these	elusive	cells	can	indeed	be	targeted.			
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Figure	 1:	 Representative	 imaging	 of	 osteoblastic	 osteosarcoma.	 (A)	 Macroscopic	
view	of	a	resected	osteosarcoma	infiltrating	surrounding	soft	tissue.	Conventional	X-
ray	 (B)	and	(C)	Magnetic	Resonance	 Imaging	 (MRI)	of	osteosarcoma.	 (D)	Computed	
tomography	 of	 an	 osteosarcoma	 in	 a	 15-year	 old	 patient	 (adapted	 from	 “Bone	
Cancer”	 1
st
	 Edition,	 Ed.	 Heymann	 D.,	 Academic	 Press,	 2009).	 Tumour	 tissue	 is	
composed	 by	 mineralized	 component	 detectable	 to	 X-Ray	 (*)	 and	 is	 strongly	
associated	 with	 the	 vasculature	 (arrows).	 (E)	 Typical	 histological	 view	 showing	
osteoid	 extracellular	 matrix	 produced	 by	 osteosarcoma	 cells	 (*),	 tumour	 tissue	 is	
vascularized	 (arrow	head).	 (F)	 Sarcosphere	 generated	 from	 the	human	MNNG-HOS	
osteosarcoma	cell	line	under	non-adherent	serum-free	conditions. 	
	
Table	1:	Studies	investigating	CSCs	in	osteosarcoma	
!
!
Initial	CSC	
identification/	
enrichment	method	
Osteosarcoma	cell	
lines/patient	samples	
Characterisation	of	enriched	CSC	phenotype	 Reference	
Side	population	
	
OS2000,	KIKU,	NY,	
Huo9,	HOS,	U2OS	and	
Saos2	
Sphere	formation,	stem	like	gene	expression,	in	
vivo	tumorigenicity	
(23)	
Human	primary,	U2OS		 Stem	like	genes,	sphere	formation,	drug	resistance,	
in	vivo	tumorigenicity	
(24)	
ALDH	
	
MG63	 Stem	like	gene	expression,	drug	resistance,	sphere	
formation	
(25)	
OS99-1	Hu09,	Saos-2,	
MG63	
Stem	like	gene	expression,	in	vivo	tumorigenicity	 (27)	
CD133	
	
Saos2,	MG63,	U2OS	 Stem	like	gene	expression,	side	population,	sphere	
formation	
(28)	
Human	primary		 Stem	like	genes,	side	population,	sphere	
formation,	in	vivo	tumorigenicity	
(29)	
Human	primary	(FFPE),	
MG63	
Stem	like	gene	expression	 (30)	
Human	primary	(FFPE),	
Saos2	
Stem	like	gene	expression	 (31)	
Human	primary,	Saos2,	
U2OS,	MG63,	HOS,	
MNNG/HOS,	143B	
Sphere	formation,	drug	resistance,	in	vivo	
tumorigenicity,	stem	like	gene	expression		
(32)	
CD117/Stro-1	
K7M2,	KHOS/NP,		
MNNG/HOS,		318-1,	
P932,		BCOS	
Sphere	formation,	drug	resistance,	stem	like	gene	
expression,	in	vivo	tumorigenicity	and	metastatic	
potential	
(33)	
CD271	
Human	primary	(FFPE),	
MNNG/HOS,	U2OS,	
Saos2	
Stem	like	gene	expression,	sphere	formation,	drug	
resistance,	in	vivo	tumorigenicity	
(34)	
Sphere	formation	
	
Human	primary,	MG63	 Stem	like	gene	expression	 (35)	
MG63	 Drug	resistance,	in	vivo	tumorigenicity	 (36)	
MNNG/HOS	 Stem	like	gene	expression,	drug	resistance,	in	vivo	
tumorigenicity	
(37)	
Sphere	formation,	
ALDH,	side	population	
HOS,	MG-63,	MHM,	
MNNG-HOS,	SJSA-1,		
L2531,	L3312,	OHS,	
U2OS	
Stem	like	gene	expression,	in	vivo	tumorigenicity	 (38)	
Sphere	formation	
MNNG/HOS,	Saos2,	
MG63	+	TGFβ/hypoxia	
In	vivo	tumorigenicity,	drug	resistance,	stem	like	
gene	expression	
(39)	
Sphere	formation,	
chemotherapeutic	
treatment,	ALDH	
Human	primary,	U2OS,	
MG63,	Saos-2	and	
143B,	link	to	miR-26a	
Stem	like	gene	expression,	in	vivo	tumorigenicity,	
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